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Abstract 
Background: Glioblastoma (GBM) is the most common primary brain tumor presenting self‑renewing cancer stem 
cells. The role of these cells on the development of the tumors has been proposed to recapitulate programs from 
embryogenesis. Recently, the embryonic transforming growth factor‑β (TGF‑β) protein Nodal has been shown to 
be reactivated upon tumor development; however, its availability in GBM cells has not been addressed so far. In this 
study, we investigated by an original approach the mechanisms that dynamically control both intra and extracellular 
Nodal availability during GBM tumorigenesis.
Methods: We characterized the dynamics of Nodal availability in both stem and more differentiated GBM cells 
through morphological analysis, immunofluorescence of Nodal protein and of early (EEA1 and Rab5) and late (Rab7 
and Rab11) endocytic markers and Western Blot. Tukey’s test was used to analyze the prevalent correlation of Nodal 
with different endocytic markers inside specific differentiation states, and Sidak’s multiple comparisons test was used 
to compare the prevalence of Nodal/endocytic markers co‑localization between two differentiation states of GBM 
cells. Paired t test was used to analyze the abundance of Nodal protein, in extra and intracellular media.
Results: The cytoplasmic distribution of Nodal was dynamically regulated and strongly correlated with the differen‑
tiation status of GBM cells. While Nodal‑positive vesicle‑like particles were symmetrically distributed in GBM stem cells 
(GBMsc), they presented asymmetric perinuclear localization in more differentiated GBM cells (mdGBM). Strikingly, 
when subjected to dedifferentiation, the distribution of Nodal in mdGBM shifted to a symmetric pattern. Moreover, 
the availability of both intracellular and secreted Nodal were downregulated upon GBMsc differentiation, with cells 
becoming elongated, negative for Nodal and positive for Nestin. Interestingly, the co‑localization of Nodal with 
endosomal vesicles also depended on the differentiation status of the cells, with Nodal seen more packed in EEA1/
Rab5 + vesicles in GBMsc and more in Rab7/11 + vesicles in mdGBM.
Conclusions: Our results show for the first time that Nodal availability relates to GBM cell differentiation status and 
that it is dynamically regulated by an endocytic pathway during GBM tumorigenesis, shedding new light on molecu‑
lar pathways that might emerge as putative targets for Nodal signaling in GBM therapy.
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Background
Nodal is a member of the TGF-β superfamily of secreted 
proteins that signals through the serine/threonine kinase 
receptors family triggering the phosphorylation of Smads 
2 and 3 [1]. Among a range of biological functions attrib-
uted to Nodal protein is its classical role during embry-
onic development [1–3], stem cell development and 
differentiation [4]. However, recent studies have shown 
that Nodal also regulates the maintenance of pluripo-
tency in embryonic stem cells [5], carcinogenesis [6], and 
tumor cell progression and development [7–15].
Glioblastoma (GBM; grade IV astrocytoma) is the most 
common primary brain tumor characterized by aggres-
sive invasiveness, high proliferative rate, insensitivity 
to radio- and chemotherapy and a short survival period 
[16–18]. It has been reported that the tumoral mass is 
generated by a rare fraction of cells displaying self-renew 
capacity named tumor-initiating cells [19–22] that are 
involved in tumor growth and resistance to chemother-
apy [23]. Sub-population of GBM cells with stem-like 
properties may be the source of tumors since, apparently, 
these stem cells are highly resistant to current cancer 
treatments and survive to regenerate new tumors [16, 24, 
25].
Regardless the physiological function of Nodal has 
been extensively described elsewhere during tumor 
progression and tumorigenesis, the characterization of 
Nodal availability in this context has not been addressed 
so far. In this study we have investigated by an original 
approach the dynamics of Nodal intracellular distribution 
and extracellular availability in both stem and more dif-
ferentiated GBM cells. Strikingly, we found that in GBM 
stem cells Nodal co-localizes in early endosomal vesicles 
and is abundantly available both intra and extracellularly. 
On the other hand, Nodal was found to co-localize to 
late endosomal compartments, including lysosomal vesi-
cles, and was less available in the extracellular medium 
in more differentiated GBM cells. Altogether, our results 
propose for the first time that the Nodal availability is 
controlled by an endocytic pathway during GBM tumo-
rigenesis shedding light on the molecular pathways that 
might emerge as putative targets for GBM therapy.
Methods
Cell culture
The cells were cultured as described in [26]. The human 
glioblastoma cell line GBM011 (mdGBM) [27] and OB1 
stem cells (GBMsc) [28] were obtained in previous stud-
ies. The human GBM U87MG cell line (mdGBM) was 
purchase from ATCC (Manassas, VA, USA). The experi-
ments with human cells were regulated by the license 
MS, CONEP 2340. DU145 prostate cell line was pur-
chased from the Cell Bank of Rio de Janeiro—UFRJ.
Immunocytochemistry
Permeabilization was done with 3  % Triton X-100 in 
PBS followed by 10  % BSA in PBS incubation. Primary 
anti-Nodal (1:25, rabbit, H-110, Santa Cruz Antibodies), 
anti-Nestin (1:200, Promega), anti-EEA1 (1:100, Santa 
Cruz sc5939), anti-Rab5 (1:100, Santa Cruz sc46692), 
Rab7 (1:100, Santa Cruz Antibodies sc6563) and Rab11 
(1:100, Santa Cruz sc9020) were used followed by sec-
ondary antibody incubation (1:300, Molecular Probes) 
plus DAPI nuclear stain (1 μg/1 μl). The slides for Nodal 
immunostaining were incubated with tyramide (1:100, 
TSA kit #13, Life Technologies, T-20923) and were 
mounted with Vectashield (Vector Laboratories). Leica 
TCS SP5 AOBS confocal microscope was used. The 
images were handled in Image J. Intensity and co-locali-
zation analysis was perfomed by Leica Application Suite 
(LAS), Leica Microsystems and Pearson’s correlation 
coefficient (PCC) was used for statistic quantifying colo-
calization. We analyzed three different fields for each 
marker, where we performed the co-localization analysis 
in a mean of three spheroids or 20–30 cells per field. The 
prevalence of Nodal colocalization with different endo-
cytic markers in each cell line was analyzed by Tukey’s 
test. For comparison and analysis of Nodal/endocytic 
markers between two cell lines, we used Sidak’s multiple 
comparisons test.
Western blot
RIPA buffer solution was used in the presence of protease 
inhibitors. The protein samples were separated by elec-
trophoresis and blotted to PVDF membrane, followed 
by blocking with 5 % non-fate dry milk powder in 0.1 % 
PBS-Tween and incubated overnight with primary anti-
body for Nodal. The secondary antibody used was the 
same for Nodal immunofluorescence assays. The reaction 
was developed using SuperSignal® West Pico Chemolu-
minescent Substrate (Thermo Scientific) and gray scale 
analysis of protein bands was performed using image 
software. Loading control and normalization was per-
formed through α-tubulin and actin immunobloting, and 
quantifications were performed in Image J.
Conditioned medium acquirement
OB1 stem cell and OB1 cells subjected to differentia-
tion were cultivated with DMEM in the absence of Fetal 
Serum Bovine (FSB) for 3  days to acquire Conditioned 
Medium (CM). Proteins present in the CM were pre-
cipitated with 80 % acetone at −20 °C overnight and the 
protein extracts were processed by Western Blot assays 
as described above. Here, loading control and normaliza-
tion was performed through densitometry of Coomas-
sie Blue R staining of the gel. Quantifications handled on 
Image J.
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Statistical analysis
GraphPad Prism (v6.0, La Jolla, CA) was used for ordi-
nary one-way or two-way ANOVA analysis where appro-
priate. If the ANOVA produced a significant result, post 
hoc pair-wise comparisons were tested for significance 
in which the P value was adjusted (P adj  <  0.05) by the 
Tukey’s method for multiple comparisons inside each 
group and by the Sidak’s method for multiple compari-
sons among the individual groups. Results are presented 
as mean  ±  SD and statistical relevance was defined as 
P < 0.05.
Results
Nodal protein intracellular distribution depends on GBM 
differentitation status
Nodal immunostaining was detected symmetrically dis-
tributed in the cytoplasm of OB1 stem cells (Fig.  1a), 
appearing as vesicle-like subcellular particles (Fig.  1b, 
arrow). Additionally, we noticed that the presence of 
Nodal in these cells changed along the development of 
the oncospheres. While small spheres contained only 
cells that show a symmetrical Nodal distribution (Addi-
tional file  1: Figure S1a), large ones were comprised by 
cells with distinct Nodal distributions (Additional file 1: 
Figure S1b). Nodal-positive cells were found on top of 
the oncospheres and presented Nodal immunostaining 
mainly localized to points of cell–cell contact (Addi-
tional file  1: Figure S1c–e). Nodal immunostaining was 
detected symmetrically distributed in the cytoplasm of 
cells located on the lateral edges, surrounding the whole 
oncosphere (Additional file 1: Figure S1f–h), as well as in 
the cytoplasm of cells that were directly attached to the 
substrate (Additional file 1: Figure S1i–l). The lack of the 
initially seen Nodal protein symmetrical distribution in 
some cells was most likely was due to the beginning of 
their differentiation in the interior of the oncospheres. 
Thus we conclude that Nodal is localized to vesicles-like 
particles that are symmetrically distributed in the cyto-
plasm of undifferentiated OB1 stem cells.
In GBM011 cells, Nodal immunostaining was present 
in an asymmetric pattern, characterized by a perinu-
clear distribution, with no evidence of association to the 
plasma membrane (Fig.  1c). Nodal positive vesicle-like 
particles were observed, and unlike OB1 stem cells, pre-
sented a perinuclear localization (Fig. 1c, arrow).
To test whether Nodal asymmetric distribution is 
restricted to mdGBM cells or if it is a broader marker 
of differentiated cancer cells, we also tested and found 
the same asymmetry in the well-described prostate cell 
line DU145 that has been shown to transduce the Nodal 
signaling pathway (Additional file 2: Figure S2). Thus we 
Fig. 1 Nodal protein intracellular distribution depends on GBM 
differentitation status. a Nodal immunostaining was symmetrically 
distributed in the cytoplasm of OB1 stem cells. b Optical slices pro‑
jected on the YZ axis showing a virtual reconstruction of the cell seen 
in “a” (asterisk). Nodal was localized to vesicle‑like particles (arrow). c In 
GBM011 cells, Nodal immunostaining was found in a rare population 
of cells and was asymmetrically localized to a perinuclear region. 
Vesicle‑like particle were also observed (arrow)
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conclude that Nodal immunostaining is found in asym-
metric perinuclear localization in more differentiated 
GBM cells during interphase.
Nodal asymmetric cytoplasmic distribution shifts to a 
symmetric distribution in dedifferentiated GBM cells
We next tested whether the Nodal asymmetric and sym-
metric distributions represent markers of the differentia-
tion state of GBM cells. We reasoned that the asymmetric 
distribution, found in mdGBM cells, would shift to a 
symmetric distribution, if these cells were induced to 
a less differentiated status. To test this hypothesis, we 
have used the U87MG cell line induced with a dediffer-
entiation protocol. We verified the differentiation sta-
tus through Nanog Western Blot, in OB1, differentiated 
OB1, U87MG and U87MG dedifferentiated cells (Addi-
tional file 3: Figure S3). In the original differentiated cells, 
Nodal immunostaining was asymmetrically located in 
the perinuclear area (Additional file 4: Figure S4, arrows). 
Conversely, when U87MG cells were induced to dedif-
ferentiate (U87MG-O), the Nodal asymmetric distribu-
tion shifted to a symmetric pattern (Additional file  4: 
Figure S4b–d, arrows), similar to that observed in OB1 
stem cells. We also found that U87MG-O cells upregulate 
Nodal protein intracellular levels, reinforcing our data 
obtained on OB1 cells. This finding indicates that Nodal 
cytoplasmic distribution and levels are dynamically regu-
lated and strongly correlate with the differentiation status 
of GBM cells.
Nodal protein intra and extracellular levels are reduced 
upon GBM differentiation
To better understand the dynamics of Nodal protein dur-
ing the transition between a stem cell like to a more dif-
ferentiated cell behavior of GBM cells, we have quantified 
the abundance of intracellular Nodal in OB1 stem cells 
induced to differentiate. To confirm the differentiation 
of the cells, we evaluated cell morphology and the dis-
tribution of Nestin, a marker for differentiating progeni-
tor cells [29]. OB1 stem cells grown as spheres, in the 
absence of FBS, were Nestin-negative and Nodal positive 
(Fig.  2a, b). Differentiated OB1 cells presented a spread 
out morphology, were Nestin-positive and mostly nega-
tive for Nodal (69 %, n = 66 cells; Fig. 2c, d). As expected, 
in OB1 stem cells subjected to differentiation there was a 
decreased in Nodal protein levels (Fig. 2e; n = 3).
As Nodal is a member of the TGFβ superfamily, we 
asked whether the extracellular levels of Nodal are also 
dynamically regulated during GBM tumorigenesis. Pro-
tein quantification of the conditioned medium showed 
that Nodal extracellular levels were downregulated as 
GBMsc were induced to differentiate (Fig.  2f ). These 
results show that not only Nodal distribution is altered 
but also its intra and extracellular availability are reduced 
upon GBMsc differentiation.
Nodal protein co‑localizes with different endosomal 
vesicles depending on the differentiation status of GBM 
cells
Previous studies have shown that Nodal was found in 
endosomal vesicles [30]. Therefore, to elucidate whether 
the vesicle-like particles observed in stem and differen-
tiated GBM cells correspond to the same subcellular 
compartments or not or even whether they may change 
according to the differentiation status of GBM cells, we 
performed immuno co-localization of Nodal and differ-
ent endosomal proteins in OB1 and differentiated OB1 
cells (Figs.  3, 4). Nodal immunostaining in OB1 stem 
cells was found to co-localize with both early (EEA1 and 
Rab5) and late (Rab7 and Rab11) endosomes (Figs. 3, 4), 
suggesting that OB1 stem cells are continuously recycling 
and degrading Nodal. In contrast, in differentiated OB1 
cells, Nodal immunostaining was mostly co-localized 
with late (Rab7 and Rab11) endosomal vesicles (Figs.  3, 
4). These results are in agreement with a decrease in the 
levels of secreted Nodal in mdGBM cells as shown in 
Fig. 2f. It was possible to verify the same pattern and rates 
on U87MG and U87MG-O cells (Additional file 5: Figure 
S5, Additional file 6: Figure S6), suggesting that the Nodal 
endocytic processing is not specific of a cell line, relating 
to the phenotypic state. Also, our analysis of Nodal/endo-
somal markers co-localization in GBM011 cells reveal 
that the GBM primary cultures reproduced the pattern 
observed in mdGBM cells (Additional file 6: Figure S6). 
(See figure on next page.) 
Fig. 2 Nodal protein levels are dowregulated during GBM differentiation. a, b OB1 stem cells forming oncospheres were immunostained for Nodal 
(red) and Nestin (green). DAPI (blue). OB1 stem cells present Nodal immunostaining localized to vesicles‑like particles symmetrically distributed in 
the cytoplasm of GBM stem cells that are Nestin‑negative (c, d). Upon differentiation, less differentiated cells were found positive for both Nodal 
and Nestin. More differentiated GBM cells were found negative for Nodal and positive for Nestin (69 % of cells; d, asterisk). Cells presenting a less 
elongated morphology were found Nodal‑positive and Nestin‑negative (26 % of cells). e Quantification of intracellular Nodal protein in OB1 stem 
cells and upon differentiation by Western blot. Nodal protein levels decrease in 50 % upon differentiation (quantification of average across three 
separate experiments). Nodal protein normalization through α‑Tubulin immunoblotting. f Quantification of extracellular Nodal protein in protein 
precipitation of proteins present in conditioned medium by Western blot, presenting visible decrease in Nodal levels in OB1 cells upon differentia‑
tion. Nodal protein normalization through Coomassie Blue staining of gel. Data are mean ± SD. ***P < 0.001 by unpaired t test, n = 3)
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Fig. 3 Nodal protein co‑localizes with different endosomal vesicles depending on the differentiation status of GBM cells. Representative images of 
Nodal immunostaining with endosomal markers. In OB1 stem cells, Nodal co‑localized with both early (EEA1 and Rab5) and late (Rab7 and Rab11) 
endosomes. In contrast, in differentiated OB1 cells, Nodal immunostaining was mostly co‑localized with late (Rab7 and Rab11) endosomal vesicles
Page 7 of 10Oliveira‑Nunes et al. Cancer Cell Int  (2016) 16:46 
Thus, we conclude that Nodal availability might be con-
trolled by an endocytic pathway, in a differentiation sta-
tus dependent manner.
Based on the results obtained in this study, it is possible to 
summarize in an illustration the dynamics of Nodal distri-
bution and availability during differentiation of GBM stem 
cells, as well as the endocytic mechanisms that may regu-
late Nodal during GBM tumorigenesis (Fig. 5). Briefly, the 
GBM stem cells present a large amount of Nodal symmetri-
cally distributed in their cytoplasm and presenting similar 
co-localization with both early (EEA1 and Rab5) and late 
(Rab7 and Rab11) endosomal vesicles. After differentiation, 
an asymmetric distribution of Nodal is seen in the cyto-
plasm, mostly limited to the perinuclear region. Moreover, 
the levels of Nodal in the cells are reduced and its co-locali-
zation with endosomal vesicles changes, showing a decrease 
in its association with early (EEA1 and Rab5) endosomes 
and increase in its association with late (Rab7 and Rab11) 
endosomes. The dedifferentiation of the cells can return 
these characteristics back those seen in the stem cells.
Discussion
We provide novel data regarding Nodal protein dynam-
ics during GBM tumorigenesis, a process that remains 
poorly characterized. Besides Nodal has already been 
shown as a substantial engine disposed by different types 
of cancer, its availability and dynamics has not been 
addressed so far. Since we consider the understand-
ing of basic regulation of cancer machinery a funda-
mental factor for its approach, our study quest a better 
understanding of Nodal protein in a subcellular level 
on GBM. Using an original approach, we analyzed the 
dynamics of Nodal distribution and availability in GBM 
cells with distinct differentiation status. Through detailed 
subcellular immunofluorescence analysis, we showed for 
the first time that Nodal is dynamically regulated dur-
ing GBM cell differentiation, with clear differences found 
between the stem and the more differentiated cells. We 
were able to observe not only that the Nodal cytoplas-
mic distribution varied between GBMsc and mdGBM, 
but also to confirm that it is strongly dependent upon the 
differentiation status to which each cell type is induced. 
Even more interestingly, we showed that the availabil-
ity of Nodal is regulated by different endocytic path-
ways during GBM tumorigenesis, being associated with 
Fig. 4 Nodal mostly co‑localizes to Rab7 and Rab11 in more dif‑
ferentiated GBM cells. Pearson’s coefficient of relative amount of 
co‑localization of endosomal markers/Nodal in OB1 and differenti‑
ated OB1 cell cultures (quantification of average across three separate 
fields, each containing an average of three to four spheroids—OB1 
cells—or 20–30 cells—differentiated OB1 cells). Data means are ± SD. 
***P < 0.001 by two‑way ANOVA for repeated measures followed by 
Tukey’s test for correction of the P value
Fig. 5 Illustration of the dynamics of Nodal distribution and avail‑
ability during differentiation of GBM stem cells and of the endocytic 
mechanisms that may regulate Nodal during GBM tumorigenesis. 
The GBM stem cells shows a large amount of Nodal symmetrically 
distributed in their cytoplasm. The presence of Nodal in these cells is 
co‑localization with both early (EEA1 and Rab5) and late (Rab7 and 
Rab11) endosomes. Upon differentiation, an asymmetric distribu‑
tion of Nodal is found in the perinuclear region of the cells. In these 
cells, the intra and extracellular levels of Nodal are reduced and its 
co‑localization with endosomes changes. There is a decrease in the 
association of Nodal with early (EEA1 and Rab5) endosomes and 
increase in its association with late (Rab7 and Rab11) endosomes. The 
characteristics seen in the stem cells can be returned after the dedif‑
ferentiation of the cells
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distinct endosomal vesicles depending on the differentia-
tion status of the cells.
Vesicular intracellular trafficking has important roles 
in cell signaling coupling processing and endocytosis in 
signal-receiving cells [31, 32]. Endosomal markers are 
restrained at specific subcellular compartments, which 
dictates the stage of endosomal maturation of the vesi-
cle [32]. Rab5 proteins are localized in early endosomes, 
which play essential roles in endocytosis, signaling regu-
lation, motility and invasion [33–35]. Moreover, Rab5/
EEA1 vesicles provide faster and direct recycling than 
through recycling endosomes (1–2 vs 15–20  min) [36]. 
We found that Nodal is packed in EEA1/Rab5-positive 
vesicles in GBMsc. A possible consequence of the con-
nection between Nodal and the endocytic pathway 
through Rab5/EEA1 vesicles is a higher rate of turnover 
of endocytated Nodal back to the membrane, maintain-
ing Nodal signaling in the GBMsc itself, keeping in this 
way, high levels of Nodal in the extracellular media. This 
fact would contribute to keep cells in a more undifferen-
tiated state. In fact, previous works have show that Nodal 
inhibition forces pluripotent embryonic stem cells into a 
differentiation pathway [37].
On the other hand, Rab7-positive vesicles are a key fac-
tor for enzymatic regulation and internalization of mem-
brane surface proteins [38]. Our data show that mdGBM 
cells mostly presented Nodal co-localization with Rab7 
and Rab11. This result indicates that these cells actively 
internalize Nodal and direct it for degradation or for 
recycling endosomes. The subsequent lower rate of Nodal 
addressed to the extracellular media could contribute to 
gradually downregulate its signaling in mdGBM cells. 
Altogether, our current results suggest that the endocytic 
pathway plays a key role for Nodal availability regulation 
during GBM differentiation.
We also have observed a change in Nodal intracellular 
distribution that was dependent upon the degree of cellu-
lar differentiation. GBMsc displayed a vesicle-like pattern 
of Nodal staining symmetrically distributed in the cyto-
plasm (Fig.  1a, b, arrow). On the other hand, mdGBM 
cells stained for Nodal in a more asymmetric and peri-
nuclear fashion (Fig. 1c). We speculate that these changes 
directly result from the different vesicles that carry Nodal 
in the two cell types. EEA1/Rab5-positive vesicles would 
maintain Nodal closer to the membrane in GBMsc, 
whereas Rab7-positive vesicles would bring Nodal closer 
to the perinuclear region. As a consequence, GBMsc may 
present a higher rate of Nodal maintaining its signaling 
levels in the GBMsc itself.
Our immunostaining for OB1 stem cells showed that 
Nodal protein staining decreased as OB1 stem cells 
undergone differentiation (Fig. 2b, d). Our results clearly 
show that Nestin-positive cells are Nodal negative only 
when morphologically spread out, an additional indica-
tor of differentiation. Conversely, U87MG cells forced to 
acquire a more undifferentiated morphology, shifted back 
to a symmetric pattern of Nodal cytoplasmic distribu-
tion (Additional file 4: Figure S4). These results indicate 
that Nodal expression heavily depends on cellular dif-
ferentiation status, and we may speculate that Nodal is 
progressively downregulated during tumor development. 
In accordance, previous studies show that the TGF-β/
Activin/Nodal branch is necessary to keep the pluripo-
tent and undifferentiated state of human embryonic stem 
cells [5, 39]. Altogether, our results support the notion 
that the cancer stem cell presents a similar behavior 
to the embryonic stem cell in terms of Nodal function. 
Despite the tight correlation between Nodal signaling 
and the stem cell phenotype, we still noticed the pres-
ence of Nodal in mdGBM cells. We speculate that tumor 
cells, although they might be in a differentiation pathway, 
never fully acquire a final, normal differentiated pheno-
type—due to the innumerous transformations they have 
incurred. Furthermore, the similar pattern, presented 
by the primary culture GBM011, to the behavior of well 
established cell lines suggests that Nodal protein can dis-
play an innovative marker on primary culture and biop-
sies analysis. However, tumor heterogeneity, especially in 
GBM, consists in a possible limitation for the accuracy of 
this approach. It would be necessary to not exclude the 
possibility of the subpopulation taken in the sample be 
precisely the more differentiated subpopulation. Thus, 
multiple markers would consist on a foremost solution. 
Still, since Nodal has been correlated to cancer aggres-
siveness and resistance [6, 8, 10, 11], its verification in 
such samples would indicate the differentiation state and, 
consequently, improve prognosis.
Taken together, our results indicate for the first time 
that Nodal is consistently involved in GBM differentiation, 
since it is highly expressed in GBMsc and downregulated 
in mdGBM cells. Dedifferentiated GBM cells upregulate 
Nodal further supporting this hypothesis. This dynamics 
displayed by Nodal is tightly connected to the endocytic 
pathway in which Nodal is inserted. Our results also shed 
light on a new approach to evaluate GBM differentiation 
by analyzing Nodal protein subcellular distribution, shed-
ding light on the molecular pathways that might emerge 
as putative targets for GBM therapy.
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Additional files
Additional file 1: Figure S1. Nodal immunostaining changes along the 
development of the oncospheres. (a) Small sphere showing only cells 
that with a symmetrical Nodal distribution in the cytoplasm. (b) Large 
sphere comprised by cells with distinct Nodal distributions. (c–e) Nodal 
immunostaining (red) in OB1 stem cells placed at the top of oncospheres 
is localized to the cell membrane (green, phalloidin, asterisk). (f–h) Cells 
located at the lateral edge of oncospheres harboring different heights 
presented Nodal immunostaining symmetrically distributed in the cyto‑
plasm of cells. (i–l) Cells directly attached to the substrate also presented a 
symmetrical distribution of Nodal. (e, h, k, l) Optical slices projected on the 
YZ axis showing a virtual reconstruction of the oncosphere.
Additional file 2: Figure S2. Nodal protein is asymmetrically distributed 
in the cytoplasm of prostate cancer cells DU145. (a) Nodal immunostain‑
ing (red) is asymmetrically distributed in the perinuclear region of prostate 
cancer cells (DU145; arrow head). Nodal negative cell is highlighted 
by the asterisk. (b) Confocal image merging the bright field and Nodal 
immunostaining (red). (c) Nodal positive cells showing a perinuclear 
immunostaining (red; arrow head). (d) Confocal image merging the bright 
field and Nodal immunostaining. (e) Zoom of the immunopositive cell 
shown in d. N = nucleus.
Additional file 3: Figure S3. Differentiation status validation through 
Nanog verification. Relative expression of Nanog in OB1, differentiated 
OB1, U87MG and dedifferentiated U87MG cells (quantification of average 
across three separate experiments). Nanog protein normalization through 
Actin immunoblotting. Data are mean ± SD. ***P < 0.001 by unpaired t 
test, n = 3).
Additional file 4: Figure S4. Nodal asymmetric cytoplasmic distribu‑
tion shifts to a symmetric distribution in dedifferentiated U87MG cells. (a) 
In U87MG cells, Nodal immunostaining was found around the nucleus 
(arrows). (b) U87MG cells present Nodal immunostaining (red) symmetri‑
cally distributed in the cytoplasm of 2 different cells (asterisks). (c, d) Nodal 
was found symmetrically distributed in the cytoplasm of two different 
U87MG cells (single and double asterisk). (e) Quantification of intracellular 
Nodal protein in U87MG cells and upon dedifferentiation by Western blot. 
Nodal protein levels upregulate in 50 % upon differentiation (quanti‑
fication of average across three separate experiments. Nodal protein 
normalization through α‑Tubulin immunoblotting. Data are mean ± SD. 
***P < 0.001 by unpaired t test, n = 3).
Additional file 5: Figure S5. Nodal protein co‑localizes with different 
endosomal vesicles depending on the dedifferentiation status of GBM cell 
lines and GBM primary cultures. Representative images of Nodal immu‑
nostaining with endosomal markers. In U87MG‑O cells, Nodal co‑localized 
with both early (EEA1 and Rab5) and late (Rab7 and Rab11) endosomes. In 
contrast, in U87MG cells, Nodal immunostaining was mostly co‑localized 
with late (Rab7 and Rab11) endosomal vesicles.
Additional file 6: Figure S6. Nodal mostly co‑localizes to Rab7 and 
Rab11 in more differentiated GBM cells and in primary cultures. (a) 
Pearson’s coefficient of relative amount of co‑localization of endosomal 
markers/Nodal in U87MG‑O and U87MG cell cultures (quantification of 
average across three separate fields, each containing an average of three 
to four spheroids—OB1 cells—or 20 to 30 cells—differentiated OB1 cells). 
(b) Pearson’s coefficient of relative amount of co‑localization of endo‑
somal markers/Nodal in GBM011 cells (quantification of average across 
three separate fields, each containing an average of 20–30 cells). Data 
means are ± SD. ***P < 0.001 by two‑way ANOVA for repeated measures 
followed by Tukey’s test for correction of the P value.
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